Prague

• Single dose, open-label, laboratory blinded, randomized, 2-treatment, 2-period, 2-sequence, crossover, pivotal study to assess the relative … Ended
  2025-521732-11-00 2 2026-03-09 No medical condition
• Study to compare drug availability in the bloodstream of two oral formulations of dexketoprofen in healthy volunteers under fasting conditio … Ended
  2025-524061-24-01 2 2026-02-13 Bioequivalence clinical trial in healthy volunteers under fasting cond
• Single dose, open-label, laboratory blinded, randomized, 2-treatment, 2-period, 2-sequence, crossover, pivotal study to assess the relative … Ended
  2025-524035-39-00 2 2026-01-14 Bioavailability study in healthy volunteers under fasting conditions.
• Single-center, single-dose, open-label, laboratory-blinded, randomized, two-treatment, two-period bioequivalence (BE) study comparing the Te … Ended
  2025-523137-25-00 2 2025-11-03 Comparative bioequivalence study in healthy volunteers under fasting c
• The pivotal bioequivalence study comparing the test product to the reference product, which belongs to the group of medicines used in treatm … Ended
  2025-523325-18-00 2 2025-10-15 Bioequivalence study under fasting conditions
• A randomised, open label, three periods, three-treatment crossover study to evaluate the pharmacokinetics of alendronic acid oral formulatio … Ended
  2025-522606-20-00 3 2025-10-06 Pharmacokinetic study in healthy volunteers under fasted conditions.
• The pivotal bioequivalence study comparing the test product to the reference product, which belong to the group of medicines used in the tre … Ended
  2025-522975-27-00 2 2025-09-29 Not applicable (submitted trial is a BE study in healthy subjects).
• A Phase 3 Trial to Evaluate the Efficacy, Safety, and Tolerability of Zasocitinib Compared to Deucravacitinib in Participants With Moderate- … Ended
  2024-512497-10-00 5 2025-09-16 Moderate to Severe Plaque Psoriasis
• Randomized, open-label, replicated single-dose, 4-period, 2-sequence crossover study to assess the comparative bioavailability of test produ … Ended
  2025-523054-14-00 2 2025-09-15 not applicable (submitted trial is bioavailability)
• The pivotal bioequivalence study comparing the test product to the reference product, which belongs to the group of medicines used in treatm … Ended
  2025-522976-10-00 2 2025-09-10 Not applicable (submitted trial is a BE study in healthy subjects.
• A study to compare the effect of AVT16 and Entyvio® in subjects with moderate to severe active ulcerative colitis. Ended
  2023-507705-34-00 5 2025-08-29 Moderate to Severe Active Ulcerative Colitis
• The bioavailability study of Dapagliflozin Ended
  2025-522234-31-00 2 2025-08-20 not applicable (submitted trial is a bioequivalence study
• Phase 2b Randomized, Double-Blind Study with Phage for CF Subjects with Pseudomonas Lung Infection Ended
  2024-519856-94-00 4 2025-08-18 Cystic fibrosis
• Pharmacokinetic study of colistimethate sodium Ended
  2024-520019-41-00 3 2025-06-30 serious infections caused by selected aerobic gram-negative pathogens
• A Phase 1, Open-Label, 2-Period, 2-Formulation, Within-Subject Crossover Comparative Pharmacokinetic, Pharmacodynamic, and Safety Study of 1 … Ended
  2025-521615-39-00 3 2025-06-04 not applicable (submitted trial is a pharmacokinetic and pharmacodynam
• The pivotal bioequivalence study comparing the test product to the reference product, which belongs to the group of medicines used in treatm … Ended
  2025-521400-21-00 2 2025-05-15 Not applicable (submitted trial is a BE study in healthy subjects).
• A study to investigate the efficacy and safety of subcutaneous lunsekimig (SAR443765) compared with placebo in adult participants with moder … Ended
  2024-511549-20-00 4 2025-04-22 Dermatitis atopic
• A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2 Ended
  2024-515452-20-00 4 2025-04-01 Narcolepsy Type 2
• The pivotal bioequivalence study comparing the test product to the reference product, which belong to the group of medicines used in treatme … Ended
  2024-518988-35-00 2 2025-04-01 Not applicable (submitted trial is a bioequivalence in healthy subject
• Phase 1/2 Study of Cobolimab plus Dostarlimab in Pediatric and Young Adult Participants with Newly Diagnosed and Relapsed/Refractory Tumors Ended
  2024-511350-41-00 9 2025-03-13 Relapsed/Refractory Tumors
• Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients with … Ended
  2024-514562-40-00 4 2025-03-13 Hidradenitis suppurativa (HS)
• A randomised, open label, single dose, two periods, crossover study of the comparative pharmacokinetics of two alendronic acid formulations … Ended
  2024-519666-43-00 3 2025-03-04 not applicable (submitted trial is a pharmacokinetic study in healthy
• A Study to Understand the ability and safety of GDC-8264 in Preventing kidney Injury and Major Adverse Kidney Events following Heart Surgery Ended
  2024-513125-23-00 4 2025-02-28 Patients with moderate to high risk for cardiac surgery associated- ac
• A Phase 2, Dose-Ranging Study of LY4100511 (DC-853) in Adult Participants with Moderate-to-Severe Plaque Psoriasis Ended
  2024-512207-39-00 4 2025-01-30 Plaque Psoriasis

Showing 649–672 of 847 trials